Effects of pirfenidone on proliferation, migration, and collagen contraction of human tenon's fibroblasts in vitro

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 8, 2009, Pages 3763-3770

  Lin, Xianchai ^a   Yu, Minbin ^a   Wu, Kaili ^a   Yuan, Hongzhi ^a   Zhong, Hua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; COLLAGEN; MESSENGER RNA; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TRYPAN BLUE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ARTICLE; AUTOCRINE EFFECT; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONNECTIVE TISSUE CELL; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; INCUBATION TIME; MIGRATION INHIBITION; MITOSIS INHIBITION; MUSCLE FIBER CONTRACTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TENON FIBROBLAST; WESTERN BLOTTING; CELL CULTURE; CELL CYCLE; CELL MOTION; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; FASCIA; FIBROBLAST; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; FASCIA; FIBROBLASTS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; PYRIDONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

EID: 68349089205     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2815     Document Type: Article

References (33)

1. Lee DA. Antifibrosis agents and glaucoma surgery. Invest Ophthalmol Vis Sci. 1994;35:3789-3791.
2. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003; 44:3394-3401.
3. Khaw PT, Chang L, Wong TT, Mead AL, Daniels JT, Cordeiro MF. Modulation of wound healing after glaucoma surgery. Curr Opin Ophthalmol. 2001;12:143-148.
4. Newhouse RP, Beyrer C. Hypotony as a late complication of trabeculectomy. Ann Ophthalmol. 1982;14:685-686.
5. Jampel HD, Pasquale LR, Dibernardo C. Hypotony maculopathy following trabeculectomy with mitomycin C. Arch Ophthalmol. 1992;110:1049-1050.
6. Franks WA, Hitchings RA. Complications of 5-fluorouracil after trabeculectomy. Eye. 1991;5:385-389.
7. Higginbotham EJ, Stevens RK, Musch DC, et al. Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmology. 1996;103:650-656.
8. Parrish R, Minckler D. "Late endophthalmitis": filtering surgery time bomb? Ophthalmology. 1996;103:1167-1168.
9. Stamper RL, McMenemy MG, Lieberman MF. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. Am J Ophthalmol. 1992;114:544-553.
10. Crowston JG, Wang XY, Khaw PT, Zoellner H, Healey PR. Human serum reduces mitomycin-C cytotoxicity in human Tenon's fibroblasts. Invest Ophthalmol Vis Sci. 2006;47:946-952.
11. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;291:367-373.
12. Hewitson TD, Kelynack KJ, Tait MG, et al. Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol. 2001;14:453-460.
13. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at thetranslational level. Am J Physiol. 1999;276:L311-L318. IOVS, August 2009, Vol. 50, No. 8 Effects of Pirfenidone on Human Tenon's Fibroblasts 3769
14. Oku H, Nakazato H, Horikawa T, Tsuruta Y, Suzuki R. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol. 2002; 446:167-176.
15. Giri SN, Leonard S, Shi X, Margolin SB, Vallyathan V. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol. 1999;18:169-177.
16. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999;159:1061-1069.
17. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040-1047.
18. Di Sario A, Bendia E, Svegliati BG, et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol. 2002;37:584-591.
19. Zhang S, Shiels IA, Ambler JS, Taylor SM. Pirfenidone reduces fibronectin synthesis by cultured human retinal pigment epithelial cells. Aust N Z J Ophthalmol. 1998;26(suppl 1):S74-S76.
20. Cordeiro MF, Bhattacharya SS, Schultz GS, Khaw PT. TGF-beta1, -beta2, and -beta3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation, and migration. Invest Ophthalmol Vis Sci. 2000;41:756-763.
21. Occleston NL, Alexander RA, Mazure A, Larkin G, Khaw PT. Effects of single exposures to antiproliferative agents on ocular fibroblast- mediated collagen contraction. Invest Ophthalmol Vis Sci. 1994; 35:3681-3690.
22. Lee BS, Margolin SB, Nowak RA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab. 1998;83:219-223.
23. Clinical trials: NCT00011076, NCT00287729, NCT00754780, NCT00332033, NCT00001959. Available at http://www.clinicaltrials. gov. Accessed July 31, 2008.
24. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;289:211-218.
25. Kakugawa T, Mukae H, Hayashi T, et al. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J. 2004;24:57-65.
26. Di Sario A, Bendia E, Macarri G, et al. The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig Liver Dis. 2004;36: 744-751.
27. Spond J, Case N, Chapman RW, et al. Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulm Pharmacol Ther. 2003;16:207-214.
28. Kaneko M, Inoue H, Nakazawa R, et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol. 1998;113:72-76.
29. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342: 1350 -1358.
30. Grisanti S, Szurman P, Warga M, et al. Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study.Invest Ophthalmol Vis Sci. 2005;46:191-196.
31. Meyer-ter-Vehn T, Sieprath S, Katzenberger B, Gebhardt S, Grehn F, Schlunck G. Contractility as a prerequisite for TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest Ophthalmol Vis Sci. 2006;47:4895-4904.
32. Meyer-Ter-Vehn T, Gebhardt S, Sebald W, et al. p38 inhibitors prevent TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest Ophthalmol Vis Sci. 2006;47:1500- 1509.
33. Khaw P, Grehn F, Hollo G, et al. A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology. 2007;114:1822-1830.